Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Lymphoma, Hodgkin
- Lymphoma Non-Hodgkin
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 20 years and 90 years
- Gender
- Both males and females
Description
The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows. Registration after infor...
The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows. Registration after informed consent. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood Regular monitoring disease status and update of survival status Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood
Tracking Information
- NCT #
- NCT03117036
- Collaborators
- Samsung Genomic Institute
- Investigators
- Principal Investigator: Seok Jin Kim, MD, PhD Samsung Medical Center